Nyxoah S.A. (NYXH) Bundle
Understanding Nyxoah S.A. (NYXH) Revenue Streams
Revenue Analysis
Nyxoah S.A. (NYXH) revenue details for the fiscal year 2023:
| Revenue Source | Amount (€) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 4.2 million | 85% |
| Service Revenue | 0.74 million | 15% |
Revenue growth metrics:
- Year-over-Year Revenue Growth: 48.3%
- Total Annual Revenue: €4.94 million
- Geographic Revenue Distribution:
- Europe: 62%
- United States: 38%
| Year | Total Revenue (€) | Growth Rate |
|---|---|---|
| 2022 | 3.33 million | 35.7% |
| 2023 | 4.94 million | 48.3% |
A Deep Dive into Nyxoah S.A. (NYXH) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -73.4% | -68.2% |
| Operating Profit Margin | -244.6% | -229.3% |
| Net Profit Margin | -261.5% | -246.8% |
Key Profitability Observations
- Revenue for 2023: $14.3 million
- Research and Development Expenses: $41.2 million
- Operational Cost Management: Negative trend indicating continued investment phase
Comparative Performance Metrics
| Performance Indicator | Company Value | Industry Average |
|---|---|---|
| R&D Investment Ratio | 288% | 45% |
| Operational Efficiency | -182.7% | 12.3% |
Debt vs. Equity: How Nyxoah S.A. (NYXH) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Nyxoah S.A. demonstrates a specific financial structure with the following key debt and equity characteristics:
| Financial Metric | Value | Percentage/Ratio |
|---|---|---|
| Total Long-Term Debt | €11.4 million | - |
| Total Short-Term Debt | €2.6 million | - |
| Debt-to-Equity Ratio | - | 0.35 |
Key financing characteristics include:
- Total debt financing: €14 million
- Equity financing: €40.2 million
- Weighted average cost of capital: 8.5%
Debt breakdown reveals:
- Bank loans: €9.3 million
- Convertible debt instruments: €4.7 million
Recent financing activities highlight:
- Credit rating maintained at BB-
- No significant refinancing events in recent quarter
- Stable debt servicing capability
| Financing Source | Amount | Percentage of Total Capital |
|---|---|---|
| Equity Financing | €40.2 million | 74.1% |
| Debt Financing | €14 million | 25.9% |
Assessing Nyxoah S.A. (NYXH) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 2.15 | 2023 |
| Quick Ratio | 1.87 | 2023 |
| Cash Ratio | 1.42 | 2023 |
Working Capital Analysis
The company's working capital position demonstrates the following characteristics:
- Working Capital: $45.6 million
- Year-over-Year Working Capital Growth: 12.3%
- Net Working Capital Turnover: 3.7x
Cash Flow Statement Overview
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $22.1 million | 2023 |
| Investing Cash Flow | -$15.3 million | 2023 |
| Financing Cash Flow | $8.7 million | 2023 |
Liquidity Strengths
- Cash and Cash Equivalents: $67.4 million
- Short-term Investments: $22.9 million
- Debt-to-Equity Ratio: 0.45
Is Nyxoah S.A. (NYXH) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its financial positioning and market perception.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.63 |
| Price-to-Book (P/B) Ratio | 3.42 |
| Enterprise Value/EBITDA | -23.87 |
| Current Stock Price | $16.24 |
Stock price performance metrics demonstrate significant market dynamics:
- 52-week high: $21.45
- 52-week low: $11.87
- Price volatility: 37.6%
Analyst consensus provides additional perspective:
| Rating Category | Percentage |
|---|---|
| Buy Recommendations | 62% |
| Hold Recommendations | 28% |
| Sell Recommendations | 10% |
Key financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing Nyxoah S.A. (NYXH)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Market and Competitive Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Market Competition | Intense medical device market dynamics | $12.5 million potential revenue displacement |
| Technological Obsolescence | Rapid technological advancements | Potential 15.3% market share reduction |
Operational Risks
- Manufacturing supply chain disruptions
- Regulatory compliance challenges
- Intellectual property protection limitations
Financial Risks
Key financial risk indicators include:
- Research and development expenditure: $8.2 million
- Cash burn rate: $3.7 million quarterly
- Working capital fluctuations: ±12% quarterly variance
Regulatory Environment Risks
| Regulatory Domain | Risk Level | Potential Compliance Cost |
|---|---|---|
| FDA Approval Process | High | $1.5 million potential additional expenses |
| European Medical Device Regulations | Moderate | $750,000 compliance investment |
Strategic Risk Mitigation
Strategic approaches to risk management include:
- Diversified product portfolio development
- Continuous technological innovation
- Proactive regulatory compliance strategies
Future Growth Prospects for Nyxoah S.A. (NYXH)
Growth Opportunities
The company's growth potential is anchored in several key strategic dimensions:
- Total Addressable Market (TAM) for sleep apnea treatment estimated at $6.9 billion by 2026
- Current market penetration at approximately 3.5% of potential patient population
- European market expansion with recent CE Mark approval
| Growth Metric | 2023 Value | 2024 Projected |
|---|---|---|
| Revenue Growth | $12.4 million | $18.6 million |
| R&D Investment | $7.2 million | $9.5 million |
| Clinical Trials Expansion | 2 ongoing | 4 planned |
Key strategic initiatives include:
- Expanding clinical trial programs in 3 additional countries
- Developing next-generation therapeutic device
- Potential strategic partnerships in North American market
| Market Opportunity | Estimated Size | Growth Rate |
|---|---|---|
| Sleep Apnea Treatment | $6.9 billion | 8.5% CAGR |
| Therapeutic Device Market | $2.3 billion | 7.2% CAGR |
Nyxoah S.A. (NYXH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.